페이스메이커 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Pacemaker Market Growth & Trends:

The global pacemaker market size is expected to reach USD 7.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 5.7% from 2025 to 2030. The market is experiencing steady growth, driven by advancements in medical technology and an increasing global demand for heart rhythm management solutions. Technological innovations, such as leadless pacemakers, smaller devices, and improved battery life, have significantly enhanced the effectiveness and convenience of pacemaker implantation. Integrating remote monitoring capabilities has also improved patient care by allowing healthcare providers to track pacemaker function and patient health remotely, reducing hospital visits. In November 2024, Europe witnessed its first single-chamber, wireless cardiac pacemaker implantation at Bern University Hospital. This procedure, led by experts from the UAE, underscores the country's position as a leader in medical innovation and its commitment to training regional healthcare professionals.

The market benefits from a greater focus on treating heart conditions such as bradycardia, arrhythmias, and heart failure. As cardiovascular diseases remain one of the leading causes of death globally, the need for reliable and effective pacing devices continues to rise. Pacemakers are increasingly seen as a critical solution for improving patient outcomes, leading to their widespread adoption in hospitals and outpatient centers. With continuous advancements in pacemaker technology and a growing demand for cardiac care, the market is expected to maintain strong growth in the coming years. In November 2023, MedStar Washington Hospital Center became one of the first institutions in the U.S. to offer the Aveir DR Leadless Pacemaker System for patients with abnormally slow heart rates.

Pacemaker Market Report Highlights:

• The implantable pacemaker segment dominated the product category in 2024 with 68.0% of the market share due to its proven effectiveness in treating heart rhythm disorders and widespread adoption in clinical practice.
• In 2024, the bradycardia segment accounted for a substantial share of 27.5% by application owing to the high prevalence of bradycardia, particularly among aging populations.
• In terms of end use, the hospital segment dominated in 2024 due to the advanced healthcare infrastructure and specialized care available in hospital settings. Outpatient facilities are anticipated to grow at the fastest CAGR owing to the increasing adoption of minimally invasive procedures and shorter recovery times.
• North America held the largest share of 43.4% of the global market due to advanced healthcare infrastructure, high healthcare spending, and early adoption of innovative pacemaker technologies.
• Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period due to rising cardiovascular disease prevalence, improving healthcare access, and increasing healthcare investments in the region.
• The competition features key players implementing strategies like product launches, distribution agreements, and strategic partnerships, which have greatly expanded their market share.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
• 2.3. Competitive Insights

Chapter 3. Pacemaker Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of cardiovascular diseases (CVD)
    • 3.2.1.2. Favorable reimbursement policies
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulation and approvals
    • 3.2.2.2. Product Recalls
• 3.3. Pacemaker Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Pacemaker Market: Product Estimates & Trend Analysis

• 4.1. Global Pacemaker Market: Product Dashboard
• 4.2. Global Pacemaker Market: Product Movement Analysis
• 4.3. Global Pacemaker Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 4.4. External Pacemakers
  • 4.4.1. External pacemakers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.2. Single Chamber
    • 4.4.2.1. Single Chamber market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.3. Dual Chamber
    • 4.4.3.1. Dual Chamber market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Implantable Pacemakers
  • 4.5.1. Implantable pacemakers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5.2. Conventional
    • 4.5.2.1. Conventional market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.2.2. Single Chamber
      • 4.5.2.2.1. Single Chamber market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.2.3. Dual Chamber
      • 4.5.2.3.1. Dual Chamber market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.2.4. Biventricular Chamber
      • 4.5.2.4.1. Biventricular Chamber market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5.3. Leadless
    • 4.5.3.1. Leadless market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.3.2. Single Chamber
      • 4.5.3.2.1. Single Chamber market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.3.3. Dual Chamber
      • 4.5.3.3.1. Dual Chamber market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Pacemaker Market: Application Estimates & Trend Analysis

• 5.1. Global Pacemaker Market: Application Dashboard
• 5.2. Global Pacemaker Market: Application Movement Analysis
• 5.3. Global Pacemaker Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 5.4. Bradycardia
  • 5.4.1. Bradycardia market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Acute Myocardial Infarction
  • 5.5.1. Acute myocardial infarction market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Arrhythmias
  • 5.6.1. Arrhythmias market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6.2. Atrial Fibrillation
    • 5.6.2.1. Atrial Fibrillation market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6.3. Heart Block
    • 5.6.3.1. Heart Block market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6.4. Long QT Syndrome
    • 5.6.4.1. Long QT syndrome market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.7. Congestive Heart Failure
  • 5.7.1. Congestive heart failure market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Pacemaker Market: End Use Estimates & Trend Analysis

• 6.1. Global Pacemaker Market: End Use Dashboard
• 6.2. Global Pacemaker Market: End Use Movement Analysis
• 6.3. Global Pacemaker Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Outpatient Facilities
  • 6.5.1. Outpatient Facilities market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Cardiovascular Devices Market: Regional Estimates & Trend Analysis by Country, Product, Application, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 8.2. Company/Competition Categorization
• 8.3. Key company market share analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Osypka Medical GmbH
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Zoll Medical Corporation
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Medtronic
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. BIOTRONIK
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. MicroPort Scientific Corporation
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. MEDICO SpA
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Pacetronix
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Oscor Inc
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Boston Scientific Corporation
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Lepu Medical Technology (Beijing) Co., Ltd.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives